Versant Venture Capital VI, L.P. - Insider Trading & Ownership

Entity
Company
Location
One Sansome Street, Suite 1650, San Francisco, CA
Summary
The estimated value of insider holdings of Versant Venture Capital VI, L.P. is at least $115M dollars as of October 30, 2024. Versant Venture Capital VI, L.P. is the 10%+ Owner of Monte Rosa Therapeutics, Inc. and owns shares of Monte Rosa Therapeutics, Inc. (GLUE) stock worth about $53.2M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $28.7M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Century Therapeutics, Inc. and owns shares of Century Therapeutics, Inc. (IPSC) stock worth about $18.1M. Versant Venture Capital VI, L.P. is the 10%+ Owner of LENZ Therapeutics, Inc. and owns shares of LENZ Therapeutics, Inc. (LENZ) stock worth about $12M. Versant Venture Capital VI, L.P. is the 10%+ Owner of Tempest Therapeutics, Inc. and owns shares of Tempest Therapeutics, Inc. (TPST) stock worth about $2.56M.
All Insider Reports
All Insider Reports

Ownership of Versant Venture Capital VI, L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
GLUE Monte Rosa Therapeutics, Inc. 10%+ Owner $53.2M -$12.3M -18.8% Oct 28, 2024
BDTX Black Diamond Therapeutics, Inc. 10%+ Owner $28.7M -$1.4M -4.65% Aug 28, 2024
IPSC Century Therapeutics, Inc. 10%+ Owner $18.1M Aug 9, 2022
LENZ LENZ Therapeutics, Inc. 10%+ Owner $12M Mar 21, 2024
TPST Tempest Therapeutics, Inc. 10%+ Owner $2.56M -$967K -27.4% Aug 8, 2024
CTNM Contineum Therapeutics, Inc. 10%+ Owner Apr 9, 2024
OYST Oyster Point Pharma, Inc. 10%+ Owner Jan 3, 2023

Insider Transactions Reported by Versant Venture Capital VI, L.P.:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.